Rituximab in combination with CHOP, an effective and well-tolerated salvage regimen for diffuse large B-cell lymphoma

Objective To evaluate the clinical effect of the R-CHOP regimen (rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone) in treating refractory or relapsed diffuse large B-cell lymphoma (DLBCL), as a salvage therapy for DLBCL.